On August 28, 2026, the U.S. Food and Drug Administration approved Mimrylo (rusfertide), a first-in-class hepcidin-mimetic peptide. Takeda's same-day release states the indication as treatment of erythrocytosis in adults with polycythemia vera (PV). The product is a weekly subcutaneous injection. Approval went to Takeda Pharmaceuticals America, Inc. after priority review.
Rusfertide is not a GLP-1, GIP, or amylin drug. It is not indicated for obesity or weight loss. It is not a research-catalog "hepcidin" vial. A COA check can test whether a certificate names a real lab. It cannot turn a storefront listing into Takeda's approved product.
This is the 8:07 Industry News slot for 11 September 2026. It is not a second Research Roundup. Today's TT-P34 Phase I Parkinson peptide note stays as written.
What happened on August 28
The FDA announcement called Mimrylo the first approved PV treatment that mimics hepcidin, the hormone that regulates iron. Tanya Wroblewski, M.D., of FDA's Division of Nonmalignant Hematology, said people with PV have long managed the disease with frequent blood draws and that the approval offers a first-in-class option with the potential to reduce that burden. That is regulator language.
Takeda and The ASCO Post use the narrower labeled use: erythrocytosis in adults with PV. This article keeps that wording as the commercial indication. The FDA press text also describes a new treatment for adults with PV whose red-cell overproduction has not been adequately controlled.
Protagonist Therapeutics discovered rusfertide (PTG-300) and led development through Phase 3. Takeda holds exclusive global rights. NCT05210790 still lists Protagonist as lead sponsor.
Andrew T. Kuykendall, M.D., of Moffitt Cancer Center, the VERIFY lead investigator, said in Takeda's release that uncontrolled hematocrit can raise thrombotic risk and that phlebotomy leaves a gap. PeptidePrices reports that quote. It does not adopt "paradigm shift" marketing from the Takeda headline. Takeda says the open-label VERIFY extension is ongoing and that it is talking to regulators outside the United States. Those are next-step statements, not new efficacy tables.
What rusfertide is
Hepcidin is the principal regulator of systemic iron. In PV, red-cell overproduction proceeds while systemic iron is often low. Rusfertide is a peptide that mimics hepcidin. Takeda and the 2025 ASCO plenary coverage describe the intended effect as regulating iron distribution, limiting iron available for new red cells, and helping keep hematocrit controlled.
That mechanism is iron restriction, not incretin signaling. It is not semaglutide or tirzepatide. Sharing a weekly subcutaneous schedule with a GLP-1 is not sharing a receptor or an indication. It is also not SS-31 (elamipretide), another peptide that later received an FDA label for a different disease.
PV is a chronic myeloproliferative blood cancer. Takeda cites about 90,000 people in the United States. A central treatment goal is hematocrit below 45%. Uncontrolled hematocrit is linked to thrombotic risk. VERIFY named phlebotomy, hydroxyurea, interferon, and/or ruxolitinib as the standard-care backdrop. Rusfertide was added on top of that backdrop. It does not make PV a cured disease.
| Thing | What it is | What 28 August covers |
|---|---|---|
| Hepcidin | Endogenous iron-regulatory hormone | Class biology, not the drug |
| Rusfertide (PTG-300) | Hepcidin-mimetic peptide | Weekly SC Mimrylo |
| Mimrylo | FDA-approved Takeda brand | Erythrocytosis in adults with PV |
| VERIFY (NCT05210790) | Phase 3, rusfertide plus SOC vs placebo plus SOC | Efficacy and safety package |
| Incretin GLP-1s | Semaglutide, tirzepatide, related drugs | Not this approval |
VERIFY design
VERIFY is a global, randomized, double-blind, placebo-controlled Phase 3 study. FDA, Takeda, and the 2025 ASCO abstract agree on the core frame: 293 adults with PV who needed frequent phlebotomies despite standard care. Randomization was 1:1 to rusfertide plus standard care (n=147) or placebo plus standard care (n=146) for 32 weeks (Part 1a).
The registry, queried 11 September 2026, is active not recruiting. Actual start is 1 April 2022. Actual primary completion is 21 February 2025. Estimated completion is June 2027. Part 1a is 32 weeks of blinded add-on therapy. Completers can receive open-label rusfertide for 124 weeks. The record lists 184 locations and Protagonist as lead sponsor. Published sources use N=293. Main inclusion includes 2016 WHO PV criteria and at least 3 phlebotomies in 6 months or 5 in 1 year for inadequate hematocrit control, with hematocrit below 45% immediately before randomization.
Kuykendall, Pemmaraju, Pettit, and colleagues presented Part 1a as ASCO 2025 Late-Breaking Abstract 3 (J Clin Oncol. 2025;43(suppl 17):LBA3). The ASCO Post's 25 September 2025 plenary write-up reprints those endpoint numbers. That coverage is not a full peer-reviewed VERIFY manuscript. This article treats LBA3 plus that 2025 story as the numbered Phase 3 source, and the August 2026 FDA and Takeda texts as the approval source.
| Item | Published figure | Source |
|---|---|---|
| Phase | 3, global, double-blind, placebo-controlled | FDA, Takeda, NCT, LBA3 |
| N randomized | 293 (147 vs 146) | FDA, Takeda, LBA3 |
| Add-on SOC | Phlebotomy, hydroxyurea, interferon, and/or ruxolitinib | Takeda, NCT, LBA3 |
| Concurrent cytoreduction | 56.5% vs 55.5% | LBA3 |
| Primary window | Weeks 20 to 32 | NCT, Takeda, LBA3 |
| Response definition | Absence of phlebotomy eligibility: confirmed hematocrit at least 45% and at least 3 points above baseline, or hematocrit at least 48% | Takeda, ASCO Post 2025 |
| Open-label follow-on | Weeks 32 to 52, then longer safety | NCT, Takeda |
The primary endpoint is hematocrit control and phlebotomy avoidance in a defined window. It is not overall survival and not a thrombosis-event count.
What the numbers show
Primary (weeks 20 to 32). Response was 76.9% with rusfertide plus standard care versus 32.9% with placebo plus standard care (P < .0001). FDA used the same percentages and worded the result as no phlebotomies during the 32-week period. This article keeps Takeda's and LBA3's weeks-20-to-32 response definition as the precise claim.
Key secondaries (LBA3 / ASCO Post 2025). Mean phlebotomies, weeks 0 to 32: 0.5 versus 1.8 (P < .0001). LBA3 reports those means with SE 0.2 in each arm. Hematocrit held below 45% from baseline to week 32 in 62.6% versus 14.4% (P < .0001). PROMIS Fatigue SF-8a favored rusfertide (least-squares mean difference 1.95; P = .0268). The ASCO Post described that difference as almost two points at the same P value. MFSAF TSS7 also favored rusfertide (P = .0239). Those are symptom scores, not thrombosis-event reductions.
Safety. Takeda lists common adverse reactions in more than 15% of patients as injection-site reactions (56%) and anemia (16%). Warnings are new or worsening thrombocytosis (monitor CBC), injection-site reactions (including Grade 3), and embryo-fetal toxicity. Takeda advises against breastfeeding during treatment and for 30 days after the final dose. LBA3 Part 1a rates were injection-site reactions 55.9% versus 32.9% on placebo and anemia 15.9% versus 4.1%. Serious adverse events were 3.4% versus 4.8%. Those Part 1a counts are a plenary snapshot, not a finished 3-year safety monograph.
Kuykendall's "real confidence" line is investigator language. Katherine Walsh's 2025 discussant remark that VERIFY is "practice-changing" is discussant language. PeptidePrices does not adopt either sentence as a finding.
| Endpoint | Rusfertide plus SOC | Placebo plus SOC |
|---|---|---|
| Response, weeks 20 to 32 | 76.9% (n=147) | 32.9% (n=146); P < .0001 |
| Mean phlebotomies, weeks 0 to 32 | 0.5 | 1.8; P < .0001 |
| Hematocrit <45%, weeks 0 to 32 | 62.6% | 14.4%; P < .0001 |
| PROMIS Fatigue SF-8a | LS mean difference 1.95; P = .0268 | |
| MFSAF TSS7 | Favored rusfertide; P = .0239 | |
| Injection-site reactions (label, >15%) | 56% | |
| Anemia (label, >15%) | 16% |
Company topline and LBA3 agree on the primary percentages. They are not a full peer-reviewed VERIFY paper.
Labeled starting dose (not a consumer protocol)
FDA says treatment started at 19 mg subcutaneously once weekly and was titrated to maintain hematocrit below 45%. That is the VERIFY starting assignment. It is not a gray-market protocol.
| Setting | Reported assignment | Source |
|---|---|---|
| Starting dose | 19 mg subcutaneously, once weekly, titrated to hematocrit below 45% | FDA 28 Aug 2026 |
| Route | Once-weekly subcutaneous (self-administered in VERIFY) | FDA, Takeda, NCT |
| Titration window | First 20 weeks, then primary assessment weeks 20 to 32 | ASCO Post 2025 |
This article does not publish a home titration schedule. Prescribing belongs on the official label and with a licensed clinician treating PV.
Research-vendor vials labeled rusfertide, PTG-300, or "hepcidin mimetic" are not Mimrylo. Price is not identity. Use the vendor checklist and the COA verification guide before treating any certificate as proof of the approved product.
What this does not mean
- It is not a weight-loss or obesity approval. Mimrylo is labeled for erythrocytosis in adults with PV. It is not an incretin GLP-1.
- It is not a cure. PV remains a chronic blood cancer. The open-label VERIFY extension is still running.
- It is not a thrombosis-outcomes trial. The primary endpoint was absence of phlebotomy eligibility in weeks 20 to 32. The fetched sources do not publish a powered effect on stroke or venous thrombosis counts.
- 76.9% is not "no phlebotomy forever." It is the Part 1a response rate against 32.9% on placebo plus the same standard care.
- A 1.95-point PROMIS Fatigue difference is not a quality-of-life guarantee. It is a statistically significant secondary (P = .0268).
- Weekly 19 mg is not a catalog dose. It is the FDA-described starting assignment. This is not medical advice and not a consumer dosing protocol.
- A research-peptide storefront is not the approved drug. FDA approval of Takeda's Mimrylo does not validate gray-market peptides.
- Priority review is not a safety waiver. Injection-site reactions, anemia, thrombocytosis, and embryo-fetal warnings remain on the Takeda safety block.
- This is not a rewrite of Mounjaro's cardiovascular indication or the July 2026 PCAC compounding votes. Different molecules, different statutes.
What did not change
No PeptidePrices peptide page for rusfertide existed on 11 September 2026, and none was created. Live semaglutide and tirzepatide pages remain pages for different products. Compounding votes for other peptides did not become a Mimrylo substitute. TT-P34's Phase I Parkinson readout did not become this story. Approval does not make every hepcidin-adjacent catalog listing equivalent to Mimrylo.
Limitations
The FDA note reprints 76.9% versus 32.9% with a shorter "32-week" phrasing than Takeda's weeks-20-to-32 response definition. This article privileges the VERIFY primary window. LBA3 plus the 2025 ASCO Post are the numbered Phase 3 sources used here. A later full-text paper may add intervals and longer safety. Those extras are omitted until fetched. Takeda's 78% "uncontrolled hematocrit" and four-fold cardiovascular-risk citations are company-cited background, not VERIFY endpoints, and are not used as efficacy numbers. Kuykendall disclosed consulting and institutional research funding from Protagonist. That relationship does not erase P < .0001.
What to watch next
- The official U.S. Prescribing Information for titration and CBC monitoring.
- A full peer-reviewed VERIFY paper. LBA3 is a late-breaking abstract.
- Open-label follow-up. An extension is not a new randomized primary.
- Ex-U.S. filings. Takeda talking to other regulators is not an EMA decision.
- Storefront copy after launch. Approval does not convert a research listing into Mimrylo.
FAQs
Is rusfertide (Mimrylo) a weight-loss GLP-1?
No. It is a hepcidin-mimetic peptide approved for erythrocytosis in adults with polycythemia vera. It is not indicated for obesity or weight loss.
What did FDA approve on August 28, 2026?
Mimrylo (rusfertide) for erythrocytosis in adults with PV, as stated by Takeda. FDA called it the first approved hepcidin-mimetic treatment for this rare blood disorder. Approval went to Takeda Pharmaceuticals America, Inc., after priority review.
What did VERIFY show?
In 293 adults who still needed frequent phlebotomies on standard care, 76.9% on rusfertide plus standard care versus 32.9% on placebo plus standard care met the weeks-20-to-32 response definition (P < .0001). Mean phlebotomies were 0.5 versus 1.8. Hematocrit stayed below 45% in 62.6% versus 14.4%. Fatigue and MFSAF scores favored rusfertide.
What dose was used?
FDA says treatment started at 19 mg subcutaneously once weekly and was titrated to maintain hematocrit below 45%. That is the labeled trial starting assignment. It is not a consumer protocol.
Does a research-vendor vial equal Mimrylo?
No. The approved product is Takeda's Mimrylo. A certificate or a catalog name is not the NDA product.
Is rusfertide a cure for polycythemia vera?
No. VERIFY tested hematocrit control and phlebotomy burden over 32 blinded weeks. The open-label extension is ongoing. PV remains a chronic disease.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. Mimrylo (rusfertide) is an FDA-approved hepcidin-mimetic peptide for erythrocytosis in adults with polycythemia vera. Nothing here is a dosing protocol, an availability claim for a research vendor, or a recommendation to obtain an unapproved product.
Continue your research
- TT-P34 Phase I (today's Research Roundup)
- SS-31 (elamipretide)
- ARA-290 human trial doses
- FDA PCAC compounding votes
- Mounjaro cardiovascular approval
- Semaglutide prices
- Tirzepatide prices
- How to verify a peptide COA
- COA Authenticity Checker
Sources
- U.S. Food and Drug Administration. FDA approves first drug of its kind for polycythemia vera, a rare blood disorder. 28 August 2026
- Takeda. Takeda receives U.S. FDA approval of MIMRYLO (rusfertide) for polycythemia vera. 28 August 2026
- ClinicalTrials.gov NCT05210790. A Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (VERIFY)
- The ASCO Post. FDA approves rusfertide for erythrocytosis in adults with polycythemia vera. 31 August 2026
- Kuykendall AT, et al. Results from VERIFY. J Clin Oncol. 2025;43(suppl 17):LBA3
- Helwick C. Adding the hepcidin mimetic rusfertide to standard of care in polycythemia vera. The ASCO Post. 25 September 2025